NCT00003494 - Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 26, 1996

Primary Completion Date

May 26, 2002

Study Completion Date

May 26, 2002

Conditions

Bronchial Alveolar; Tumor

Interventions

DRUG

Antineoplaston therapy (Atengenal + Astugenal)

"Patients with Recurrent or Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston